Crossmark

Influence of Breakthrough Therapy Designation in the United States on Oncology Drug Development Timelines in Japan

Crossref DOI link: https://doi.org/10.1007/s40290-018-0236-8

Published Online: 2018-05-26

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tanaka, Makoto https://orcid.org/0000-0001-8570-3992
Matsumaru, Naoki

Tsukamoto, Katsura
License Information

Text and Data Mining valid from 2018-05-26
More Information

Article History

First Online: 26 May 2018

Compliance with Ethical Standards

:

: The authors received no financial support for the research, authorship, and/or publication of this article.

: Makoto Tanaka is an employee of Astellas Pharma Inc, and belongs to a laboratory (Global Regulatory Science) supported by Otsuka Pharmaceutical Co Ltd. Naoki Matsumaru belongs to a laboratory (Global Regulatory Science) supported by Otsuka Pharmaceutical Co Ltd. Katsura Tsukamoto belongs to a laboratory (Global Regulatory Science) supported by Otsuka Pharmaceutical Co Ltd.